---
document_datetime: 2025-12-02 06:49:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/amversio.html
document_name: amversio.html
version: success
processing_time: 0.1206322
conversion_datetime: 2025-12-28 10:17:58.654469
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Amversio

[RSS](/en/individual-human-medicine.xml/67551)

##### Authorised

This medicine is authorised for use in the European Union

betaine anhydrous Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Amversio](#news-on)
- [More information on Amversio](#more-information-on-amversio-1623)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Amversio is a medicine used to treat homocystinuria, an inherited disease where the amino acid homocysteine cannot be broken down and therefore builds up in the body. This causes a wide range of symptoms, including impaired vision, weak bones and circulatory problems.

It is used with other treatments, such as vitamin B6 (pyridoxine), vitamin B12 (cobalamin), folate and a special diet.

Amversio is a 'generic medicine'. This means that Amversio contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Cystadane. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Amversio contains the active substance betaine anhydrous.

Expand section

Collapse section

## How is Amversio used?

Amversio can only be obtained with a prescription. Treatment with Amversio should be supervised by a doctor who has experience in the treatment of patients with homocystinuria.

Amversio is available as a powder to be taken by mouth. It should be dissolved fully in water, juice, milk, formula or food before being taken. The standard dose of Amversio is 50 mg per kilogram of body weight twice a day. The dose can be adjusted depending on the response to treatment (monitored by measuring the level of homocysteine in the blood). The aim of the treatment is to keep blood levels of homocysteine below 15 micromoles or as low as possible. This is usually achieved within a month.

For more information about using Amversio, see the package leaflet or contact your doctor or pharmacist.

## How does Amversio work?

Betaine is a natural substance that is extracted from sugar beet. It reduces the high homocysteine levels in the blood of patients with homocystinuria by transforming homocysteine into the amino acid methionine. This helps to improve the symptoms of the disease.

## How has Amversio been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Cystadane, and do not need to be repeated for Amversio.

As for every medicine, the company provided studies on the quality of Amversio. There was no need for 'bioequivalence' studies to investigate whether Amversio is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood. This is because Amversio is a water-soluble medicine with a composition very similar to the reference medicine's and both products are therefore expected to be absorbed in the same way in the gut.

## What are the benefits and risks of Amversio?

Because Amversio is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Amversio authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Amversio has been shown to be comparable to Cystadane. Therefore, the Agency's view was that, as for Cystadane, the benefits of Amversio outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Amversio?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Amversio have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Amversio are continuously monitored. Suspected side effects reported with Amversio are carefully evaluated and any necessary action taken to protect patients.

## Other information about Amversio

Amversio received a marketing authorisation valid throughout the EU on 5 May 2022.

Amversio : EPAR - Medicine overview

Reference Number: EMA/216901/2022

English (EN) (143.11 KB - PDF)

**First published:** 28/07/2022

[View](/en/documents/overview/amversio-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-862)

български (BG) (167.68 KB - PDF)

**First published:**

28/07/2022

[View](/bg/documents/overview/amversio-epar-medicine-overview_bg.pdf)

español (ES) (143.4 KB - PDF)

**First published:**

28/07/2022

[View](/es/documents/overview/amversio-epar-medicine-overview_es.pdf)

čeština (CS) (163.67 KB - PDF)

**First published:**

28/07/2022

[View](/cs/documents/overview/amversio-epar-medicine-overview_cs.pdf)

dansk (DA) (143.59 KB - PDF)

**First published:**

28/07/2022

[View](/da/documents/overview/amversio-epar-medicine-overview_da.pdf)

Deutsch (DE) (146.23 KB - PDF)

**First published:**

28/07/2022

[View](/de/documents/overview/amversio-epar-medicine-overview_de.pdf)

eesti keel (ET) (131.22 KB - PDF)

**First published:**

28/07/2022

[View](/et/documents/overview/amversio-epar-medicine-overview_et.pdf)

ελληνικά (EL) (165.93 KB - PDF)

**First published:**

28/07/2022

[View](/el/documents/overview/amversio-epar-medicine-overview_el.pdf)

français (FR) (144.28 KB - PDF)

**First published:**

28/07/2022

[View](/fr/documents/overview/amversio-epar-medicine-overview_fr.pdf)

hrvatski (HR) (162.6 KB - PDF)

**First published:**

28/07/2022

[View](/hr/documents/overview/amversio-epar-medicine-overview_hr.pdf)

italiano (IT) (142 KB - PDF)

**First published:**

28/07/2022

[View](/it/documents/overview/amversio-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (170.66 KB - PDF)

**First published:**

28/07/2022

[View](/lv/documents/overview/amversio-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (163.83 KB - PDF)

**First published:**

28/07/2022

[View](/lt/documents/overview/amversio-epar-medicine-overview_lt.pdf)

magyar (HU) (164.09 KB - PDF)

**First published:**

28/07/2022

[View](/hu/documents/overview/amversio-epar-medicine-overview_hu.pdf)

Malti (MT) (166.27 KB - PDF)

**First published:**

28/07/2022

[View](/mt/documents/overview/amversio-epar-medicine-overview_mt.pdf)

Nederlands (NL) (142.96 KB - PDF)

**First published:**

28/07/2022

[View](/nl/documents/overview/amversio-epar-medicine-overview_nl.pdf)

polski (PL) (166.43 KB - PDF)

**First published:**

28/07/2022

[View](/pl/documents/overview/amversio-epar-medicine-overview_pl.pdf)

português (PT) (143.8 KB - PDF)

**First published:**

28/07/2022

[View](/pt/documents/overview/amversio-epar-medicine-overview_pt.pdf)

română (RO) (161.34 KB - PDF)

**First published:**

28/07/2022

[View](/ro/documents/overview/amversio-epar-medicine-overview_ro.pdf)

slovenčina (SK) (163.69 KB - PDF)

**First published:**

28/07/2022

[View](/sk/documents/overview/amversio-epar-medicine-overview_sk.pdf)

slovenščina (SL) (160.53 KB - PDF)

**First published:**

28/07/2022

[View](/sl/documents/overview/amversio-epar-medicine-overview_sl.pdf)

Suomi (FI) (141.16 KB - PDF)

**First published:**

28/07/2022

[View](/fi/documents/overview/amversio-epar-medicine-overview_fi.pdf)

svenska (SV) (159.58 KB - PDF)

**First published:**

28/07/2022

[View](/sv/documents/overview/amversio-epar-medicine-overview_sv.pdf)

Amversio : EPAR - Risk-management-plan summary

English (EN) (155.94 KB - PDF)

**First published:** 28/07/2022

**Last updated:** 28/07/2022

[View](/en/documents/rmp-summary/amversio-epar-risk-management-plan-summary_en.pdf)

## Product information

Amversio : EPAR - Product information

English (EN) (308 KB - PDF)

**First published:** 28/07/2022

[View](/en/documents/product-information/amversio-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-215)

български (BG) (328.59 KB - PDF)

**First published:**

28/07/2022

[View](/bg/documents/product-information/amversio-epar-product-information_bg.pdf)

español (ES) (221.34 KB - PDF)

**First published:**

28/07/2022

[View](/es/documents/product-information/amversio-epar-product-information_es.pdf)

čeština (CS) (314.28 KB - PDF)

**First published:**

28/07/2022

[View](/cs/documents/product-information/amversio-epar-product-information_cs.pdf)

dansk (DA) (286.58 KB - PDF)

**First published:**

28/07/2022

[View](/da/documents/product-information/amversio-epar-product-information_da.pdf)

Deutsch (DE) (315.38 KB - PDF)

**First published:**

28/07/2022

[View](/de/documents/product-information/amversio-epar-product-information_de.pdf)

eesti keel (ET) (252.62 KB - PDF)

**First published:**

28/07/2022

[View](/et/documents/product-information/amversio-epar-product-information_et.pdf)

ελληνικά (EL) (335.25 KB - PDF)

**First published:**

28/07/2022

[View](/el/documents/product-information/amversio-epar-product-information_el.pdf)

français (FR) (316.18 KB - PDF)

**First published:**

28/07/2022

[View](/fr/documents/product-information/amversio-epar-product-information_fr.pdf)

hrvatski (HR) (271.54 KB - PDF)

**First published:**

28/07/2022

[View](/hr/documents/product-information/amversio-epar-product-information_hr.pdf)

íslenska (IS) (271.05 KB - PDF)

**First published:**

28/07/2022

[View](/is/documents/product-information/amversio-epar-product-information_is.pdf)

italiano (IT) (300.96 KB - PDF)

**First published:**

28/07/2022

[View](/it/documents/product-information/amversio-epar-product-information_it.pdf)

latviešu valoda (LV) (324.59 KB - PDF)

**First published:**

28/07/2022

[View](/lv/documents/product-information/amversio-epar-product-information_lv.pdf)

lietuvių kalba (LT) (323.11 KB - PDF)

**First published:**

28/07/2022

[View](/lt/documents/product-information/amversio-epar-product-information_lt.pdf)

magyar (HU) (304.54 KB - PDF)

**First published:**

28/07/2022

[View](/hu/documents/product-information/amversio-epar-product-information_hu.pdf)

Malti (MT) (318.63 KB - PDF)

**First published:**

28/07/2022

[View](/mt/documents/product-information/amversio-epar-product-information_mt.pdf)

Nederlands (NL) (226.81 KB - PDF)

**First published:**

28/07/2022

[View](/nl/documents/product-information/amversio-epar-product-information_nl.pdf)

norsk (NO) (260.07 KB - PDF)

**First published:**

28/07/2022

[View](/no/documents/product-information/amversio-epar-product-information_no.pdf)

polski (PL) (312.28 KB - PDF)

**First published:**

28/07/2022

[View](/pl/documents/product-information/amversio-epar-product-information_pl.pdf)

português (PT) (263.1 KB - PDF)

**First published:**

28/07/2022

[View](/pt/documents/product-information/amversio-epar-product-information_pt.pdf)

română (RO) (314.88 KB - PDF)

**First published:**

28/07/2022

[View](/ro/documents/product-information/amversio-epar-product-information_ro.pdf)

slovenčina (SK) (311.89 KB - PDF)

**First published:**

28/07/2022

[View](/sk/documents/product-information/amversio-epar-product-information_sk.pdf)

slovenščina (SL) (304.49 KB - PDF)

**First published:**

28/07/2022

[View](/sl/documents/product-information/amversio-epar-product-information_sl.pdf)

Suomi (FI) (252.27 KB - PDF)

**First published:**

28/07/2022

[View](/fi/documents/product-information/amversio-epar-product-information_fi.pdf)

svenska (SV) (256.55 KB - PDF)

**First published:**

28/07/2022

[View](/sv/documents/product-information/amversio-epar-product-information_sv.pdf)

05/05/2022

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Amversio : EPAR - All authorised presentations

English (EN) (49.93 KB - PDF)

**First published:** 28/07/2022

[View](/en/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-262)

български (BG) (61.96 KB - PDF)

**First published:**

28/07/2022

[View](/bg/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_bg.pdf)

español (ES) (54.08 KB - PDF)

**First published:**

28/07/2022

[View](/es/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.22 KB - PDF)

**First published:**

28/07/2022

[View](/cs/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (56.5 KB - PDF)

**First published:**

28/07/2022

[View](/da/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (55.2 KB - PDF)

**First published:**

28/07/2022

[View](/de/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (52.8 KB - PDF)

**First published:**

28/07/2022

[View](/et/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (58.15 KB - PDF)

**First published:**

28/07/2022

[View](/el/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_el.pdf)

français (FR) (54.9 KB - PDF)

**First published:**

28/07/2022

[View](/fr/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.08 KB - PDF)

**First published:**

28/07/2022

[View](/hr/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (56.42 KB - PDF)

**First published:**

28/07/2022

[View](/is/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_is.pdf)

italiano (IT) (53.54 KB - PDF)

**First published:**

28/07/2022

[View](/it/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (57.43 KB - PDF)

**First published:**

28/07/2022

[View](/lv/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (58.31 KB - PDF)

**First published:**

28/07/2022

[View](/lt/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.73 KB - PDF)

**First published:**

28/07/2022

[View](/hu/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (60.11 KB - PDF)

**First published:**

28/07/2022

[View](/mt/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.94 KB - PDF)

**First published:**

28/07/2022

[View](/nl/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (55.7 KB - PDF)

**First published:**

28/07/2022

[View](/no/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_no.pdf)

polski (PL) (58.91 KB - PDF)

**First published:**

28/07/2022

[View](/pl/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_pl.pdf)

português (PT) (54.32 KB - PDF)

**First published:**

28/07/2022

[View](/pt/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_pt.pdf)

română (RO) (57 KB - PDF)

**First published:**

28/07/2022

[View](/ro/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (59.84 KB - PDF)

**First published:**

28/07/2022

[View](/sk/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (55.52 KB - PDF)

**First published:**

28/07/2022

[View](/sl/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (47.31 KB - PDF)

**First published:**

28/07/2022

[View](/fi/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.01 KB - PDF)

**First published:**

28/07/2022

[View](/sv/documents/all-authorised-presentations/amversio-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Amversio Active substance betaine International non-proprietary name (INN) or common name betaine anhydrous Therapeutic area (MeSH) Homocystinuria Anatomical therapeutic chemical (ATC) code A16AA06

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:

## Authorisation details

EMA product number EMEA/H/C/005637

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

SERB SA

Avenue Louise 480 1050 Brussels Belgium

Opinion adopted 24/02/2022 Marketing authorisation issued 05/05/2022

## Assessment history

## Initial marketing authorisation documents

Amversio : EPAR - Public assessment report

Adopted

Reference Number: EMA/203554/2022

English (EN) (400.68 KB - PDF)

**First published:** 28/07/2022

[View](/en/documents/assessment-report/amversio-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Amversio

Adopted

Reference Number: EMA/CHMP/83287/2022

English (EN) (156.56 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/smop-initial/chmp-summary-opinion-amversio_en.pdf)

#### News on Amversio

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

#### More information on Amversio

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 08/06/2023

## Share this page

[Back to top](#main-content)